BRAIN Biotech Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
268
- Stock Symbol
-
BNN
- Investments
-
14
- Share Price
-
$2.83
- (As of Friday Closing)
BRAIN Biotech General Information
Description
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
Contact Information
Website
www.brain-biotech.comCorporate Office
- Darmstädter Strasse 34-36
- 64673 Zwingenberg
- Germany
Corporate Office
- Darmstädter Strasse 34-36
- 64673 Zwingenberg
- Germany
BRAIN Biotech Stock Performance
As of 13-Nov-2026, BRAIN Biotech’s stock price is $2.83. Its current market cap is $61.8M with 21.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.83 | $2.85 | $2.51 - $4.48 | $61.8M | 21.8M | 5.76K | -$0.75 |
BRAIN Biotech Financials Summary
As of 30-Jun-2026, BRAIN Biotech has a trailing 12-month revenue of $53.6M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 |
|---|---|---|---|---|
| EV | 73,707 | 55,871 | 53,080 | 99,185 |
| Revenue | 53,612 | 55,191 | 59,383 | 59,042 |
| EBITDA | (6,158) | (5,398) | (4,638) | (2,108) |
| Net Income | (16,301) | (12,957) | (12,067) | (8,834) |
| Total Assets | 67,816 | 77,819 | 99,110 | 75,087 |
| Total Debt | 31,617 | 10,011 | 14,663 | 4,932 |
BRAIN Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BRAIN Biotech Comparisons
Industry
Financing
Details
BRAIN Biotech Competitors (3)
One of BRAIN Biotech’s 3 competitors is c-LEcta, a Formerly PE-Backed company based in Leipzig, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| c-LEcta | Formerly PE-Backed | Leipzig, Germany | ||||
| Conagen | Corporate Backed or Acquired | Bedford, MA | ||||
| Lonza Group | Corporation | Basel, Switzerland |
BRAIN Biotech Patents
BRAIN Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4732825-A1 | An antioxidant composition comprising a cinnamic acid derivative | Pending | 25-Oct-2024 | ||
| WO-2026087745-A1 | An antioxidant composition comprising a cinnamic acid derivative | Pending | 25-Oct-2024 | ||
| WO-2025247966-A1 | Process for protein production in methylotrophic yeast host cell. | Pending | 29-May-2024 | ||
| EP-4461740-A1 | A modified yeast strain for low alcohol fermentation | Pending | 12-May-2023 | ||
| EP-4461741-A1 | A modified yeast strain for low alcohol fermentation | Pending | 12-May-2023 | C07K14/395 |
BRAIN Biotech Signals
BRAIN Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BRAIN Biotech Investments & Acquisitions (14)
BRAIN Biotech’s most recent deal was a Secondary Transaction - Private with Breatec. The deal was made on 20-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Breatec | 20-May-2025 | Secondary Transaction - Private | Specialty Chemicals | ||
| Biocatalysts | 24-Nov-2023 | Secondary Transaction - Private | Specialty Chemicals | ||
| SolasCure | 27-Mar-2023 | Later Stage VC | Drug Discovery | ||
| Breatec | 01-Feb-2022 | Merger/Acquisition | Specialty Chemicals | ||
| Biocatalysts | 12-May-2021 | Secondary Transaction - Private | Specialty Chemicals |
BRAIN Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Chemicals
Industry
Rank
Percentile
Specialty Chemicals
Subindustry
Rank
Percentile
BRAIN Biotech Exits (1)
BRAIN Biotech’s most recent exit was on 01-Jan-2011 from MONTEIL Cosmetics International. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MONTEIL Cosmetics International | 01-Jan-2011 | Completed |
|
BRAIN Biotech Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| WeissBioTech | Ascheberg, Estonia | 2002 | |
| AnalytiCon Discovery | Potsdam, Germany | 2000 | |
| Biocatalysts | Cardiff, United Kingdom | 1983 |
BRAIN Biotech FAQs
-
When was BRAIN Biotech founded?
BRAIN Biotech was founded in 1993.
-
Where is BRAIN Biotech headquartered?
BRAIN Biotech is headquartered in Zwingenberg, Germany.
-
What is the size of BRAIN Biotech?
BRAIN Biotech has 268 total employees.
-
What industry is BRAIN Biotech in?
BRAIN Biotech’s primary industry is Biotechnology.
-
Is BRAIN Biotech a private or public company?
BRAIN Biotech is a Public company.
-
What is BRAIN Biotech’s stock symbol?
The ticker symbol for BRAIN Biotech is BNN.
-
What is the current stock price of BRAIN Biotech?
As of 13-Nov-2026 the stock price of BRAIN Biotech is $2.83.
-
What is the current market cap of BRAIN Biotech?
The current market capitalization of BRAIN Biotech is $61.8M.
-
What is BRAIN Biotech’s current revenue?
The trailing twelve month revenue for BRAIN Biotech is $53.6M.
-
Who are BRAIN Biotech’s competitors?
c-LEcta, Conagen, and Lonza Group are competitors of BRAIN Biotech.
-
What is BRAIN Biotech’s annual earnings per share (EPS)?
BRAIN Biotech’s EPS for 12 months was -$0.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process